HCV Markers and Liver Disease at the End of Chemotherapy in 114 Children With Acute Leukemia
| . | Serum HCV-RNA at the End of Chemotherapy . | Not Tested . | ||
|---|---|---|---|---|
| . | Positive . | . | Negative . | . |
| N patients (114 cases) | 56 (49%) | 55 (48%) | 3 (3%) | |
| Anti-HCV positive | 10/56 (18%) | 4/55 (7%) | 0/3 | |
| Mean ALT* peak ±SD during chemotherapy | 486.46 (±342.37) | †P = .08 | 380.65 (±303.42) | 224.3 (±253.6) |
| Patients with abnormal ALT levels at chemotherapy withdrawal | 34/56 (64%) | ‡P = .01 | 20/55 (36%) | 1/3 |
| ALT* (±SD) at chemotherapy withdrawal | 101.26 (±122.66) | †P = .04 | 58.95 (±95.18) | 41 (±22.51) |
| Patients with liver biopsy | 25 | 11 | 0/3 | |
| Histologic diagnosisρ | ||||
| NSRH | 3/25 | 2/11 | ||
| CLH | 5/25 | 4/11 | ||
| CPH | 12/25 | 3/11 | ||
| CAH | 5/25 | 2/11 | ||
| . | Serum HCV-RNA at the End of Chemotherapy . | Not Tested . | ||
|---|---|---|---|---|
| . | Positive . | . | Negative . | . |
| N patients (114 cases) | 56 (49%) | 55 (48%) | 3 (3%) | |
| Anti-HCV positive | 10/56 (18%) | 4/55 (7%) | 0/3 | |
| Mean ALT* peak ±SD during chemotherapy | 486.46 (±342.37) | †P = .08 | 380.65 (±303.42) | 224.3 (±253.6) |
| Patients with abnormal ALT levels at chemotherapy withdrawal | 34/56 (64%) | ‡P = .01 | 20/55 (36%) | 1/3 |
| ALT* (±SD) at chemotherapy withdrawal | 101.26 (±122.66) | †P = .04 | 58.95 (±95.18) | 41 (±22.51) |
| Patients with liver biopsy | 25 | 11 | 0/3 | |
| Histologic diagnosisρ | ||||
| NSRH | 3/25 | 2/11 | ||
| CLH | 5/25 | 4/11 | ||
| CPH | 12/25 | 3/11 | ||
| CAH | 5/25 | 2/11 | ||
Alanine aminotransferase; normal values ≤42 IU/L.
HCV-RNA positive versus HCV-RNA negative group. P calculated by t-test.
HCV-RNA positive versus HCV-RNA negative group. P calculated by χ 2 test.
ρ NSRH, nonspecific reactive hepatitis; CLH, chronic lobular hepatitis; CPH, chronic persistent hepatitis; CAH, chronic active hepatitis.